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Conclusions:
Parenteral methotrexate (25 mg/week) was not superior to placebo in preventing relapses of UC in patients who achieved steroid-free response during induction therapy.
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Introduction
Ulcerative colitis (UC) is a recurrent, chronic inflammatory bowel disease affecting the colon and leading to clinical symptoms, including fecal urgency, bloody diarrhea, abdominal pain, weight loss and fatigue. For patients with mild-moderate UC despite therapy with aminosalicylates, the therapeutic options include biologics or thiopurines.
While thiopurines are markedly less expensive than the biologic drugs, they are associated with potentially serious side effects including pancreatitis, leukopenia, and lymphoma. [1] [2] [3] Biological therapies, including anti-TNF agents (infliximab, adalimumab, golimumab) or anti-adhesion molecules (vedolizumab) are effective, but are expensive and also not without risks. 4 MTX is an orally, subcutaneously, intramuscularly, or intravenously administered folate antagonist that was developed in 1948 for the treatment of leukemia. MTX targets thymidylate biosynthesis and the enzyme thymidylate synthase. 5, 6 Methotrexate is converted intracellularly to MTX-polyglutamates and reduces cell proliferation, increases the rate of apoptosis of T cells, raises anti-inflammatory endogenous adenosine concentrations and alters cytokine production. The rationale behind the use of highdose MTX in cancer chemotherapy is the promotion of starvation of cancer cells by eliminating purine and pyrimidine precursors, thus leading to decreased cell proliferation due to insufficient DNA and RNA synthesis. Oral or parenteral low-dose MTX has significantly decreased toxicity compared to high dose therapy and is used in several autoimmune diseases, including polyangiitis, psoriasis and rheumatoid arthritis.
However, the mechanisms of the therapeutic effects of low-dose therapy, in contrast to high-dose therapy, remain incompletely understood. 7 In inflammatory bowel diseases (IBD), MTX's clinical efficacy in inducing and maintaining clinical remission has been established for steroid-dependent Crohn's disease (CD) in adults and also in children refractory or intolerant to thiopurine therapy. [8] [9] [10] [11] [12] [13] [14] In contrast to CD, the role of MTX in UC is controversial. In the first prospective, placebo-controlled study, oral low dose (12.5 mg) MTX weekly was not more efficacious than placebo. 15 Since then, however, observational studies have demonstrated effectiveness of MTX if given parenterally similar to the dosing used in M A N U S C R I P T 
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Patients
Eligible patients were 18 to 70 years of age and had active UC, defined by a Mayo Score of at least 6 points or higher and moderate-to severe active disease on sigmoidoscopy (Mayo endoscopic subscore ≥ 2) extending more than 15 cm from the anal verge. The Mayo Scoring system ranges from 0 -12 points and is a composite index consisting of three clinical and one endoscopic variables (stool frequency, rectal bleeding, physician's global assessment and endoscopy evaluation). 21 The endoscopic subscore was assigned by the site endoscopist using standardized Mayo endoscopic score photographs, which had been distributed to all sites. In addition to the Mayo score, at least one of the following criteria had to be met for entry in the study: a) failure Patients could continue oral and/or rectal therapy with mesalamine or corticosteroids but had to be on a stable regimen for at least 2 weeks before screening. The following medications had to be discontinued before inclusion: thiopurines for at least 2 weeks;
anti-TNF agents, vedolizumab and investigational agents for at least 4 weeks before inclusion in the study. Due to known interference with the metabolism of methotrexate, use of probenecid, trimethoprim/sulfamethoxazole, sulfasalazine, acitrecin and streptozocin were not allowed in the trial.
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Randomization and treatment
The 
Screening, baseline and follow-up
Screening procedures were performed 7 to 28 days before the baseline visit. These 
Definitions of outcome measures
The partial Mayo Score was used to measure outcomes at week 16 and determine eligibility for randomization. 21 Clinical response was defined as a reduction from baseline in the partial Mayo score of ≥ 2 points and at least 25%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0-1 point and a partial Mayo score ≤5. Clinical remission was defined as a partial Mayo score of ≤ 2 points with no individual subscore exceeding 1 point.
Primary and secondary endpoints
The primary outcome was relapse-free survival in the maintenance period, which was comprised of two components, both of which needed to be met to be categorized as 
Statistical analyses
Baseline characteristics were analyzed with the use of descriptive statistics. Fisher's exact and chi-square tests were used to compare categorical variables across groups.
Continuous variables were analyzed using Student's t-tests or Wilcoxon rank-sum tests Table S1a ).
However, when analyzing the groups based on previous exposure to a biologic, no Eighty-four patients were randomized at week 16 to either continuation with placebo (n=40) or MTX 25 mg weekly (n=44). Of these 25/40 (63%) and 27/44 (61%) of patients were in steroid free remission and 15/40 (37%) and 17/44 (39%) of patients were in steroid free response in the placebo and the MTX group, respectively. The baseline characteristics between the groups were similar (Table 1) . Overall, 60% (24/40) and 66% (29/44) of patients in the placebo and the MTX group, respectively, discontinued the therapy before week 32 of the maintenance period (p=0.71; Figure 1 ). Reasons for discontinuation of therapy were lack of efficacy in 22 patients in each group.
Numerically more patients experienced adverse events leading to discontinuation in the MTX vs the placebo group (5 vs 2) and 2 patients dropped out of the MTX group due to M A N U S C R I P T
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loss of follow-up or non-compliance with study medication. Thirty-one patients completed the week 32 visit of the maintenance period (week 48 of the trial).
The primary outcome defined as relapse-free survival without need for additional therapies such as steroids, immunosuppressants, or biologics and remission at week 48 did not differ between the groups (p=0.78, Figure 2 Figure S1 ).
Additionally, when controlling for prior TNF use, there was no significant difference in relapse free survival when comparing MTX and placebo (Hazard Ratio 0.92, 95% CI 0.55 -1.54).
FCP concentrations at screening, week 16 and week 48
At screening, the majority of the patients had FCP values above 250 mg/kg (≥250 mg/kg n=134; 75%). There were 32 (18%) and 13 (7%) patients with FCP values >50 -<250 mg/kg and ≤ 50 mg/kg, respectively (supplemental material Table S9 ). The median FCP concentrations in patients with steroid-free response or remission declined significantly from 657 mg/kg at screening to 185 mg/kg at week 16, compared to patients who failed the induction regimen (637 mg/kg at screening and 607 mg/kg at last visit; p=0.04). Among the 134 patients with FCP ≥250 mg/kg at screening, 93 (69%) had FCP levels of <250 mg/kg and 69 (51%) had FCP ≤50 mg/kg at week 16. Steroid free
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response or remission and a FCP <250 mg/kg was found in 56 (42%) patients while steroid-free remission and a FCP≤50 mg/kg was achieved in 54 (40%) patients at week 16.
Of the 84 patients randomized into the maintenance period, 24%, 33% and 43% had FCP concentrations of ≤50 mg/kg, >50 -<250 mg/kg and ≥250 mg/kg at week 16, respectively. Stratifying patients into these 3 different groups according to the FCP concentrations at week 16 showed similar results regarding clinical outcome during the maintenance period (Table 3) .
Adverse events
The most common adverse event (AE) in the open label Induction period was nausea, which occurred in 20.1% of patients (Table 4 ). In the maintenance period, significantly more patients reported an AE in the MTX compared to the placebo group (p=0.03), but there were no significant differences in types of AE's except a suggestion of a higher occurrence of nausea in the MTX group. Due to LFT elevation MTX was reduced to 15 mg in 3 patients (1 patient in induction, who was later on randomized to placebo and experienced a relapse and 2 patients in maintenance, of whom 1 finished the study in remission). None of the patients in the MTX group had a serious AE; one serious AE occurred in a patient in the placebo group who was hospitalized for a gastrointestinal infection and successfully treated with antibiotics and continued in the study. The results of the MERIT-UC and METEOR studies highlight the importance of conducting multiple randomized, controlled trials to definitively establish or refute the efficacy of a therapy.
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Our study complements the French METEOR study, which suggested clinical efficacy of MTX in inducing remission in patients with UC. 18 The steroid-free remission in our trial at week 16 is in line with the 32% steroid-free remission rate reported in the METEOR trial. With caution, one can qualitatively compare these data to other recent studies.
The steroid-free remission rates for azathioprine or infliximab monotherapy in the UC-SUCCESS trial were 24% and 22%, respectively. 32 A recent meta-analysis of induction trials revealed a 10% remission rate for placebo-treated patients with active UC. In METEOR, the complete Mayo score, which is a composite score of a clinical and endoscopic assessment, was not significantly different between MTX and placebo after 16 weeks of therapy. 18 However, the results of the partial Mayo score alone without taking into account the endoscopy results suggested potential efficacy of MTX in UC with significant improvement of bowel frequency and absence of rectal bleeding.
Carbonel, et al. speculated that the observed discrepancy in the METEOR trial may be due to the sites' proficiency in assessing the degree of mucosal inflammation in the context of the Mayo endoscopic scoring system. 18, 36 In contrast to our study, METEOR did not require endoscopically active inflammation for inclusion, which also may have influenced the outcome by favoring a placebo response. Similar to METEOR, our study did not have central reading, but the fact that 93% of patients had elevated FCP levels of > 50 mg/kg at inclusion indirectly corroborates the likely presence of significant inflammation in the majority of patients.
The MERIT-UC study design was based, in part, on the study by Feagan and the North American Crohn's Study Group Investigators, which demonstrated the effectiveness of MTX in the maintenance of remission in CD. 9 In contrast to that study, in which fewer than 5% had experienced failure of thiopurine therapy before inclusion in the trial, nearly two-thirds of the randomized population in our study had previously failed therapies with thiopurines and/or biologics. However, thiopurine or mesalamine failure only and no exposure to biologics before inclusion in the trial was not associated with the likelihood of achieving steroid-free clinical remission at week 16 in our patient population.
Consistent with our a priori sample size calculations, nearly two-thirds of the randomized patients failed to achieve the primary outcome of steroid-free clinical and M A N U S C R I P T
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endoscopic remission at the end of the study without disease exacerbation or need for additional therapies during the maintenance period. This was similar to the results of Hawthorne's landmark placebo-controlled withdrawal study among patients with UC treated with azathioprine for at least 6 months, where relapse rates were 59% and 39%
for placebo and azathioprine, respectively. 37 Moreover, in a recent meta-analysis of maintenance trials, the pooled estimate of maintenance of remission with placebo was 19% (95% CI11% to 30%) 33 . Thus, the lack of benefit observed relative to placebo is unlikely to be attributable to a higher than projected success rate among the placebotreated patients. mg/kg with clinical and endoscopic remission was described. 39 Post hoc analyses using FCP concentrations with a cutoff of <150 mg/kg for mucosal inflammation at week 16 yielded similar results (data not shown).
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Over the 48-week trial period we did not detect any new safety signals for MTX at a parenteral dose of 25 mg/week. There was only one serious adverse event due to disease exacerbation with hospitalization, which occurred in the placebo group.
However, significantly more adverse events, all graded as mild in severity, occurred in the MTX group and a numerically higher number of patients on MTX stopped therapy due to occurrence of an adverse event during the maintenance period. Overall a higher incidence of nausea appeared to be the primary cause of the difference in rates of adverse events.
This trial had a few limitations. The trial was powered to detect a 25% difference between placebo and MTX. As such, we cannot fully exclude a treatment effect of MTX in the range of 10%-15% compared to placebo. Given the current results, one would need to randomize 500-700 patients to conclusively exclude this possibility. However,
given the overall similarity of the relapse rates and the multiple negative subgroup analyses, it is unlikely that a larger study would have come to a different conclusion.
Due to financial constraints, we did not perform central reading of the sigmoidoscopies, which in the last 5 years has become standard for trials in patients with IBD. 40 However, the sigmoidoscopy scoring did not play a major role for the outcome of the trial given that the majority of patients relapsed with the need of additional therapies before the final visit. We also did not assess the degree of mucosal healing by endoscopy before randomization at week 16, but used the biomarker FCP as a surrogate marker, which has been shown to correlate with endoscopic and clinical outcomes in similar trials. 32, 39 In conclusion, MERIT-UC is the first randomized, placebo-controlled trial to provide .0 (12.0-13.9) *There were no significant differences between groups in the maintenance period. TNF denotes tumor necrosis factor, 6-MP denotes 6-mercaptopurine. Table S9 : Endoscopy score at baseline, stratified by baseline fecal calprotectin:
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Endo score 2 n=106
Endo Score 3 n=73 <50 mg/kg; n=13 9 (9%) 4 (6%) >50 mg/kg and <250 mg/kg; n=32 
